Gastrin: A Distinct Fate of Neurogenin3 Positive Progenitor Cells in the Embryonic Pancreas

Abstract

Neurogenin3⁺ (Ngn3⁺) progenitor cells in the developing pancreas give rise to five endocrine cell types secreting insulin, glucagon, somatostatin, pancreatic polypeptide and ghrelin. Gastrin is a hormone produced primarily by G-cells in the stomach, where it functions to stimulate acid secretion by gastric parietal cells. Gastrin is expressed in the embryonic pancreas and is common in islet cell tumors, but the lineage and regulators of pancreatic gastrin⁺ cells are not known. We report that gastrin is abundantly expressed in the embryonic pancreas and disappears soon after birth. Some gastrin⁺ cells in the developing pancreas co-express glucagon, ghrelin or pancreatic polypeptide, but many gastrin⁺ cells do not express any other islet hormone. Pancreatic gastrin⁺ cells express the transcription factors Nkx6.1, Nkx2.2 and low levels of Pdx1, and derive from Ngn3⁺ endocrine progenitor cells as shown by genetic lineage tracing. Using mice deficient for key transcription factors we show that gastrin expression depends on Ngn3, Nkx2.2, NeuroD1 and Arx, but not Pax4 or Pax6. Finally, gastrin expression is induced upon differentiation of human embryonic stem cells to pancreatic endocrine cells expressing insulin. Thus, gastrin⁺ cells are a distinct endocrine cell type in the pancreas and an alternative fate of Ngn3+ cells.

Introduction

The islets of Langerhans are composed of 4 main endocrine cell types: beta cells secreting insulin, alpha cells secreting glucagon, delta cells secreting somatostatin, and PP cells secreting pancreatic polypeptide. These cells all derive from endocrine progenitor cells in the embryonic pancreas, marked by expression of the transcription factor neurogenin3 (Ngn3) [1], [2]. Ngn3⁺ cells also give rise to epsilon cells expressing ghrelin, which disappear around 10 days after birth in mice [3]. A hierarchy of transcription factors orchestrates the formation of endocrine cells from Ngn3⁺ progenitors, and mutations in such factors perturb or skew the specification of endocrine cell types. The mechanisms that control the formation of endocrine cells are under intense investigation, in part in the context of efforts to generate transplantable beta cells from embryonic stem cells for the treatment of diabetes.

In parallel to its function in the developing pancreas, Ngn3 controls the formation of enteroendocrine cells in the gastrointestinal tract, which secrete, among others, the hormones secretin, gastrin, GIP, GLP, somatostatin and CCK [4], [5]. While Ngn3 appears to be a master regulator of the generic gut/pancreas endocrine program, it is not clear why different hormones are produced by the pancreatic and the intestinal derivatives of Ngn3⁺ cells. Here we focus on gastrin, a hormone secreted from endocrine G cells located mainly in the gastric antrum [6]–[8]. The gastrin peptide induces acid secretion and gastric motility, and stimulates mucosal proliferation [9]–[11]. Gastric G cells derive from Ngn3⁺ enteroendocrine progenitor cells [4], and their formation requires Nkx2.2 and Arx in addition to Ngn3 [12], [13]. Interestingly, although Ngn3 positive cells are present in the mouse embryonic gut by embryonic day 12.5 [14], the expression of gastrin in the stomach begins only postnataly, so that in fetal life, gastrin is mostly found in the pancreas, in both rodents and humans [15]–[17]. Pancreatic gastrin expression disappears after birth, but can reappear pathologically in the form of gastrin-secreting neuroendocrine tumors (gastrinomas), most of which are malignant [18], [19]. Very little is known about the origins and the molecular determinants of pancreatic gastrinomas and fetal pancreatic gastrin expression. Here we use a combination of expression analysis, genetic lineage tracing and gene knockouts to study gastrin expression in the embryonic pancreas. We demonstrate that G cells represent a distinct, 6th endocrine cell type in the embryonic pancreas, and an alternative fate of Ngn3 endocrine progenitor cells.

Results

Expression of gastrin in the embryonic pancreas

To study gastrin expression in the pancreas at high resolution, we used immunostaining and confocal microscopy. In adult mice, gastrin⁺ cells were observed as expected in the stomach but not in the pancreas (not shown). Consistent with previous reports on gastrin mRNA expression [17], we observed a particularly dramatic abundance of gastrin⁺ cells in explants of e12.5 pancreata cultured for 3 days (Fig. 1A). This observation was repeated in e14.5 embryonic pancreas where numerous gastrin⁺ cells were seen (Fig. 1B). By immunofluorescence, in both samples, gastrin⁺ cells appeared to be nearly as abundant as insulin⁺ cells. FACS analysis of dissociated embryonic pancreata confirmed this observation, demonstrating that 0.6% of the cells expressed gastrin while 0.7% expressed insulin; Fig. 1C and Fig. S1). Gastrin expression declined with embryonic age, essentially disappearing by post-natal day 7 (Fig. 1D).

Figure 1. Gastrin is abundantly expressed in the embryonic pancreas, and disappears after birth.

A. Expression of gastrin in e12.5 mouse pancreas explanted for 3 days. The image was generated by merging 4 confocal slices (Z-stack). Scale bar = 100 µm. B. In vivo expression of gastrin throughout the pancreas of an e14.5 mouse embryo. The image was generated by merging 11 confocal slices (Z-stack). C. Quantification of gastrin and insulin expression in E14.5 mouse embryo, using flow cytometry after intracellular staining for hormones. X-axis shows relative intensity of flurophore labeling insulin, whereas the y axis shows relative intensity of flurophore labeling gastrin. 0.6% of the cells label gastrin, but not insulin (quadrant Q1), and 0.7% of the cells are labeled with insulin, but not gastrin (quadrant Q4). The 0.04% of cells showing double labeling likely reflects background. D. Expression of gastrin in the mouse pancreas at different developmental ages. All images were taken on a Nikon C1 confocal microscope at a 20× or 60× magnification. Scale bar, 100 µm.

We then characterized the expression of gastrin in the e15.5 mouse embryonic pancreas, and determined the specific cell type expressing gastrin. Co-staining for gastrin and each islet hormone revealed that gastrin⁺ cells did not co-express insulin or somatostatin (Fig. 2A, B). In contrast, gastrin⁺ cells often co-expressed glucagon (53%), ghrelin (22%) or pancreatic polypeptide (17%) (Fig. 2C–E and 2K). Glucagon and ghrelin are co-expressed in endocrine cells during pancreas development. In order to determine whether there are gastrin+ cells that do not co-express these two hormones we co-stained for gastrin, glucagon and ghrelin and found gastrin+ cells that did not express ghrelin or glucagon (Fig. 2F). To further test if there were gastrin⁺ cells that did not express any of the known pancreatic hormones, we co-stained for gastrin and a cocktail of antibodies directed against insulin, glucagon, ghrelin, pancreatic polypeptide and somatostatin. As shown in Fig. 2G–H and Fig. S2, there were many gastrin⁺ cells that did not express any other pancreatic hormone (40%, Fig. 2K). Similar results were obtained when a different gastrin antibody was used to stain the pancreas of the gerbil, Psammomys obesus, demonstrating that our findings are not limited to mice. At e22 (equivalent to mouse e15.5), gastrin⁺ cells were readily identified which did not stain for either insulin or glucagon (Fig. 2I). Additionally, we stained e22 Psammomys obesus pancreata with the same cocktail used on mouse pancreata and observed gastrin⁺ cells that do not express any other pancreatic hormone (Fig. 2J).

Figure 2. Presence of gastrin-expressing cells that do not stain for other islet hormones.

Images in panels A–H are from E15.5 mouse embryos. Arrows indicate cells co-expressing gastrin and other hormones, whereas arrowheads represent cells that express only gastrin. A–E. Co-staining for gastrin and insulin (A) or somatostatin (B) reveals no overlap. Co-staining for gastrin and glucagon (C), ghrelin (D) and pancreatic polypeptide (E) reveals some overlap, but some gastrin positive cells are negative for the other hormones. F. Triple staining for glucagon (green), gastrin (red) and ghrelin (blue) reveals some cells that stain only for gastrin. G–H. Co-staining for gastrin (red) and a cocktail of antibodies against insulin, glucagon, somatostatin, pancreatic polypeptide and ghrelin (G, H, green) reveals some cells that stain only for gastrin. I. Staining for gastrin (DAKO) reveals some gastrin⁺ cells that are negative for insulin and glucagon in e22 Psammomys obesus. J. Co-staining for gastrin (red) and a cocktail of antibodies against insulin, glucagon, somatostatin, pancreatic polypeptide and ghrelin (green) in e22 Psammomys obesus, reveals cells that stain only for gastrin. K. Quantification of cells expressing gastrin with glucagon, ghrelin, pancreatic polypeptide or all pancreatic hormenos as percentage of all cells expressing gastrin at E15.5 (at least 100 cells were counted from different pancreata (n>5)). Scale bar, 100 µm. Values are presented as mean ± SE.

Most existing gastrin antibodies, including those used for the above experiments, cross-react with Cholecystokinin (CCK), a similar hormone that shares with gastrin the amino acid sequence that binds the CCKB receptor and has been reported in the embryonic pancreas. However, CCK expression was only reported in mice from gestational day 16 and beyond, and nearly all CCK⁺ cells co-express glucagon [6], suggesting that our immunostaining identified gastrin⁺ and not CCK⁺ cells. To further confirm this, we used an antibody that does not cross react with CCK (Abnova) and, using this specific antibody, demonstrated gastrin-expressing cells at e15.5 (Fig. S3). As an additional proof, our mRNA analysis (see below) is specific for gastrin, further validating the identification of gastrin. Taken together, these results show that gastrin⁺ cells represent a distinct hormone cell type generated in the embryonic pancreas.

Gastrin is expressed in cells positive for Nkx2.2, Nkx6.1 and low Pdx1

To begin and define the transcriptional machinery underlying the genesis of pancreatic gastrin⁺ cells, we co-stained embryonic pancreata for gastrin and key transcription factors. Most gastrin⁺ cells expressed Nkx6.1, Nkx2.2 and stained weakly for Pdx1 (Fig. 3). Gastrin cells never expressed high levels of Pdx1, which is a hallmark of beta-cells.

Figure 3. Transcription factors expressed in gastrin⁺ cells.

Gastrin⁺ cells in e15.5 pancreas express Nkx6.1, Nkx2.2 and lower levels of Pdx1. Yellow arrows mark the cells in the insets. Scale bar, 100 µm.

Gastrin expressing cells originate from Ngn3⁺ progenitor cells

Genetic lineage tracing studies have shown that Ngn3⁺ cells give rise to all endocrine cells in the pancreas [1], as well as most enteroendocrine cells in the intestine, including G cells [5]. To determine if gastrin⁺ cells derived from Ngn3-expressing progenitors, we used transgenic mice that express Cre recombinase driven by a BAC containing the Ngn3 promoter, combined with an indelible Cre reporter transgene (ngn3-Cre; Rosa26-LSL-YFP). Co-staining of e15.5 pancreata for YFP and gastrin revealed that all gastrin⁺ cells are YFP⁺ (Fig. 4). This result indicates that all gastrin+ cells in the embryonic pancreas are progeny of cells that previously expressed Ngn3. Additionally, examination of ngn3 ^−/− pancreata at e15.5 showed no staining for gastrin, in contrast to an abundant signal in wild type littermates (Fig. 5A). Similar results were obtained in RT-PCR densitometry analysis of RNA extracted from wild type (41,893 arbitrary units) and ngn3 ^−/− (1,592 arbitrary units) pancreata at e14.5 (Fig. 5A). Significant reduction in gastrin RNA levels was also observed in microarray analysis of ngn3 ^−/− pancreata at e12.5 (Fig. 5C). Thus, gastrin⁺ cells represent a 6^th fate of Ngn3⁺ pancreatic endocrine progenitor cells.

Figure 4. Pancreatic gastrin cells derive from Ngn3+ endocrine progenitors.

Co-staining for gastrin (red) and the progeny of Ngn3⁺ cells (anti-GFP, green) in Ngn3-Cre;Rosa26-LSL-YFP e15.5 mice reveals that all gastrin⁺ cells have passed through a Ngn3-expressing stage. Scale bar, 100 µm.

Figure 5. Transcription factors required for gastrin expression in the embryonic pancreas.

A. No expression of gastrin in Ngn3^−/− pancreata is shown by immunofluorescence staining and significant gastrin reduction by RT-PCR at e14.5. Densitometry measurement of gastrin RNA levels (imageJ) shows that gastrin expression in ngn3^+/+ pancreata is markedly reduced in ngn3 KO (from 41,893 to 1,592; arbitrary units, the same area was picked for both bands). B. No expression of gastrin in Nkx2.2^−/− pancreata is shown by immunofluorescence staining. Microarray analysis shows reduced expression of gastrin RNA in Nkx2.2^−/−, NeuroD1^−/− and double knockout embryos at e14.5. Values are presented as mean ± SE. C. Reduced expression of gastrin in Ngn3^−/− and Arx^−/− but not in Pax4^−/− embryos at e12.5 (microarray analysis). Values are presented as mean ± SE. D. Pax6^−/− embryonic pancreata have reduced numbers of gastrin⁺ glucagon⁺ cells, but gastrin⁺ glucagon− cells are still observed. Scale bar, 100 µm for all panels.

Down-stream transcription factors required for pancreatic gastrin expression

To dissect out the additional genetic requirements for gastrin⁺ cell formation in the developing pancreas, we examined embryonic pancreata from mice deficient for key transcription factors known to affect the formation of specific endocrine cell types.

nkx2.2-deficient embryos did not show gastrin staining (Fig. 5B), and microarray analysis of nkx2.2 ^−/− pancreata revealed a 70% decrease in the level of gastrin mRNA compared with wild type. We also observed a decrease in the expression of gastrin mRNA in the pancreas of neuroD1 mutants, as well as in mice doubly deficient for nkx2.2 and neuroD1 (Fig. 5B).

Mice deficient for arx showed 70% reduction in the levels of gastrin mRNA (Fig. 5C), in contrast to pax4 ^−/− embryos, which had a slight elevation in gastrin levels compared to wild type (Fig. 5C). However pax4^−/− embryos did not reveal any elevation in gastrin by immunostaining (data not shown). Finally, we examined pax6 ^−/− embryos. These mutants had no glucagon+ gastrin+ cells (presumably reflecting the requirement for Pax6 in the formation of alpha cells), but glucagon⁻ gastrin+ cells could be observed in normal numbers, indicating that Pax6 is not necessary for the formation of G cells in the pancreas (Fig. 5D).

These results indicate that gastrin expression in the embryonic pancreas is totally dependent on Ngn3, and to a lesser extent dependent on Nkx2.2, NeuroD1 and Arx, but not on Pax4 or Pax6.

Gastrin is induced in human ES cells directed to differentiate to pancreatic endocrine cells

Considerable effort is being invested in the development of protocols for directed differentiation of embryonic stem cells to insulin-producing beta cells that could be transplanted to cure diabetes. Most of these protocols rely on step-wise differentiation aimed to recapitulate embryonic development of beta cells, from definitive endoderm to pancreatic and endocrine progenitor cells, and finally into hormone-expressing cells. We reasoned that such protocols, which give rise to cultures containing a mix of pancreatic hormone expressing cells, could be generating gastrin-expressing cells as well. To test this idea we performed quantitative RT-PCR analysis on human embryonic stem cells differentiated into pancreatic endocrine cells using a modified method that was similar to published protocols [20], [21]. As shown in Fig. 6, gastrin expression was absent when cells were differentiated into definitive endoderm and pancreatic endoderm (day 8). However, there was a rapid induction of gastrin expression as cells were differentiated into endocrine cells. The kinetics of gastrin expression closely mirrored expression of insulin. Staining for gastrin in these cells reveal gastrin positive cells (Fig. 6C) which all co-expressed other hormones, consistent with the notion that endocrine cells generated in vitro are immature and polyhormonal. This finding suggests that, as in rodent, human ESC-derived pancreatic endocrine progenitor cells are competent to differentiate into gastrin⁺ cells. Since beta-cells are the sought-after product of these protocols it is desirable, and perhaps necessary, to reduce the expression of by-products such as gastrin in order to improve efficiency.

Figure 6. Gastrin expression in human embryonic stem cells.

A–B. Quantitative RT-PCR on RNA extracted from human embryonic stem cells, directed to differentiate into definitive endoderm, pancreatic progenitor cells, endocrine progenitor cells, and hormone expressing cells. Note that the kinetics of gastrin induction are similar to those of insulin expression. Values are normalized to beta tubulin and expression differences are relative to definitive endoderm (DE). C. Staining human embryonic stem cells directed to hormone expressing cells for gastrin, insulin, glucagon and somatostatin reveals gastrin positive cells (different samples).

Discussion

Pancreatic G cells as a distinct cell type

G cells are well characterized in the adult stomach, where their product, gastrin, serves a clear physiological function - reducing the pH in the lumen of the stomach and increasing stomach motility to accelerate the first steps in digestion of food. Gastric G cells were shown to co-express a number of key transcription factors including Pdx1, Nkx6.1, Nkx6.3 and Arx and to derive from Ngn3⁺ enteroendocrine progenitors. Genetic studies have identified a requirement for Pdx1, Ngn3, Nkx2.2, Pax6 and Arx in the formation of gastric G cells [5], [12],[13],[22]–[24]. It was previously observed that during embryonic development, gastrin mRNA is not expressed in the stomach but rather it is mostly expressed in the developing pancreas, in both rodents and humans [16], [17]. However the significance of this expression pattern received little attention. Here we have performed a detailed analysis of gastrin expression in the embryonic pancreas. Consistent with previous reports, we found that gastrin is abundantly expressed in the embryonic pancreas and disappears soon after birth. Gastrin is co-expressed in some embryonic alpha, epsilon and PP cells, but was never observed in beta or delta cells. Some gastrin⁺ cells appear to express this hormone alone, suggesting that they represent a distinct cell type, the pancreatic G cell. Observations in the gerbil Psammomys obesus, using a different gastrin antibody, provide independent support to this conclusion and suggest that gastrin expression is an evolutionary conserved aspect of pancreas development. At the molecular level, we found that pancreatic G cells derive from Ngn3⁺ progenitors, and express Nkx2.2, Nkx6.1 and low levels of Pdx1. We demonstrate using genetic models that gastrin expression in the fetal pancreas depends on Ngn3, Nkx2.2 and Arx (and to a lesser extent on NeuroD1) but not Pax4 or Pax6. Together, these findings identify pancreatic G cells as a distinct endocrine cell type in the pancreas, adding to the 5 other known endocrine cell types formed in this organ (see model, Fig. 7).

Figure 7. Model placing gastrin cells in the transcriptional hierarchy of endocrine cells in the pancreas.

The genetic program of gastrin expression in the pancreas is similar to that of alpha cells in that it is dependent on Arx, but also has unique features best illustrated by the formation of G cells in the pancreas of Pax6^−/− embryos, which lack alpha cells. Pancreatic G cells also resemble epsilon cells in that both gastrin and ghrelin are frequently co-expressed with glucagon in the embryonic pancreas and the expression of both shifts postnataly from pancreas to stomach. We speculate that these patterns relate to the evolutionary history of the endocrine system. Glucagon and ghrelin may represent the most ancient hormones responding to hunger, which later evolved into the multitude of more “modern” hormones with each developing its own, distinct gut/pancreas location. More work will be required to understand these dynamics. Our finding that protocols currently used for ES cell differentiation result in the production of G-cells provides evidence that these protocols recapitulate embryonic development and enrich for immature, fetal-type endocrine cells. Further steps will likely be needed to complete maturation to adult beta cells.

Significance of pancreatic gastrin expression

The function of gastrin in the embryonic pancreas is not known. Early studies have suggested that gastrin acts as a mitogen to fetal beta cells [25]–[27], but later studies found little support for this hypothesis. The issue was again raised more recently, with reports that gastrin may induce beta-cell regeneration alone, after 95% pancreatectomy [27], or if co-administered with EGF in the NOD mouse model [28], [29]. However, gastrin-deficient mice have no significant pancreatic phenotype [30] and transgenic overexpression of gastrin in beta cells also resulted in normal pancreatic development [31]. Thus, while pharmacologic administration may have an effect in some circumstances, the physiologic transient pancreatic expression of gastrin may serve no function and, as noted above, may merely reflect the evolutionary history of the endocrine system, similar to pancreatic ghrelin expression and primary transition cells [32].

We show that the expression of gastrin is detected already at e12.5. An interesting possibility is that gastrin+ cells may originate from alpha, epsilon or PP cells. We cannot exclude this possibility but believe it is unlikely. One argument is that it was previously reported that in pax6 knockout the expression of glucagon is abolished. We show that on similar pax6 knockout background the expression of gastrin is not affected.

During adult life, gastrin can be re-expressed in the pancreas in the form of functional islet cell tumors, ∼40% of which are gastrinomas [33]–[35]. The cell of origin of pancreatic gastrinomas remains unknown. They could derive from rare gastrin⁺ cells that survived in the pancreas from fetal life; from reprogramming of adult islet cells that undergo malignant transformation; or from aberrant postnatal activation of the embryonic program of endocrine differentiation. Genetic lineage tracing studies will be needed to address this problem; such studies may also reveal whether embryonic G cells are eliminated, or whether they downregulate gastrin expression and resolve to another cell type. However, such experiments are beyond the scope of this study. Finally, pancreatic islet tumors rarely express additional hormones such as Vasoactive Intestinal Polypeptide (VIP) and parathyroid hormone-related peptide (PTHRP). It will be interesting to test whether, like gastrin, these hormone are transiently expressed during normal pancreas development.

Determinants of islet cell composition

Our data on embryonic gastrin expression, together with the similar dynamics of ghrelin expression, highlight a striking difference between the composition and relative abundance of endocrine cells in the embryonic and adult pancreas. While Ngn3⁺ cells generate 6 different cell types in the fetal endocrine pancreas, postnatal processes remodel this starting population to obtain a different cell composition in the adult islet (Fig. 7). It will be interesting to study how differential rates of proliferation and survival affect this process and the molecular mechanisms that impact postnatal hormone gene expression.

Materials and Methods

Ethics Statement

The joint ethics committee (IACUC) of the Hebrew University and Hadassah Medical Center approved the study protocol for animal welfare. The Hebrew University is an AAALAC International accredited institute. Experiments with P. obesus were performed in accordance to the regulations specified under the Protection of Animals Act by the authority in Denmark, European Union and Novo Nordisk A/S.

Mice

We used either ICR mice from Harlan, Israel or knockout strains as previously described: Homozygous Ngn3-CreER (serving as Ngn3 nulls) [36], BAC transgenic Ngn3-Cre [37], ROSA26-LSL-YFP [38], Nkx2.2^−/− [32], NeuroD^−/− [39], Pax6^−/− [40], Arx^−/− [41], Pax4^−/− [42]. Experiments with P. obesus were performed in accordance to the regulations specified under the Protection of Animals Act by the authority in Denmark, European Union and Novo Nordisk A/S.

Pancreatic explants

Pancreatic buds from embryonic day (e) 12.5 mouse embryos were cultured in DMEM supplemented with 10% fetal bovine serum, containing 100 U/ml penicillin and 100 µg/ml streptomycin, as described previously [43]. Explants were cultured on microporous membranes (Whatman, nucleopore Track-Etch, diameter 13 mm, pore size 8.0 micron) and no medium was added on top of the filter, so that the tissue grew at the air/medium interface. Medium was changed every other day.

Immunostaining, antibodies and microscopy

All images are representative of at least 6 different pancreata.

Whole mount pancreas immunostaining was performed essentially as previously described [44]. For all other immunostaining, pancreata (e12.5-p7) were surgically removed and fixed in 4% buffered zinc-formalin for 2 hours at 4°C, dehydrated in an ethanol series, cleared in histoclear and embedded in Paraplast (Kendall). When required, antigen retrieval was performed using a citrate buffer and a pressure cooker. Primary antibodies used in this study included: Rabbit anti-gastrin (1∶200, Cell Marquee), rabbit anti-gastrin (1∶200, Dako), guinea pig anti-gastrin (1∶50, Progen), mouse anti-gastrin (1∶50, Abnova), guinea pig anti-insulin (1∶200, Abcam), goat anti-pancreatic polypeptide (1∶50, Abcam), mouse anti-glucagon (1∶800, Beta Cell Biology Consortium), mouse anti-somatostatin (1∶400, Beta Cell Biology Consortium), goat anti-ghrelin (1∶100, Santa Cruz), goat anti-GFP (1∶500, Abcam), goat anti-Pdx1 (1∶2,500, a generous gift of Chris Wright), mouse anti-Nkx2.2 (1∶50, Developmental Studies Hybridoma Bank) and mouse anti Nkx6.1 (1∶400, Beta Cell Biology Consortium). For DNA counterstain we used Sytox (1∶500, Invitrogen). Rabbit anti-Gastrin from Cell Marque was used in the images shown unless stated otherwise. Guinea-pig and mouse anti gastrin were used to confirm the rabbit antibody findings. The gastrin antibodies produced by Progen, Cell-Marque and DAKO cross-react with CCK (100, 50, 20% cross-reactivity respectively) whereas the Abnova antibody does not. Secondary antibodies were from Jackson immune-research, used at 1∶200. Immunofluorescence images were captured on a Nikon C1 confocal microscope or Olympus FV1000.

Flow cytometry

For FACS analysis, e14.5 pancreata or livers from wild type embryos were dissociated to single cells with trypsin and stained with guinea pig anti-insulin (1∶800, Abcam) followed by Alexa488 anti-guinea pig (1∶500, Jackson Immunoresearch), and with Rabbit anti-gastrin (1∶500, Cell Marquee) followed by Cy5 anti-rabbit (1∶800, Jackson Immunoresearch).

RT-PCR

Total RNA (n = 5) was prepared using Qiagen RNeasy microkit according to the manufacturer's protocol. Total RNA (100 ng) was used for first-strand cDNA synthesis using random primers (Roche) and reverse transcriptase (ImProm-II,Promega). We checked the existence or absence of Gastrin mRNA in wild type embryos, wild type adult pancreas and Ngn3-deficient pancreata. PCR was performed using GoTaq Green Master Mix (Promega). Primers were designed to bridge introns to avoid amplifying genomic DNA contamination if present: mGastrin: F-5′- cccagctctgtggacaagatgcctc-3′ and R-5′- gcatcctgtagctgggagcgg -3′; hB-tubulin F-5′- gatacctcaccgtggctgct -3′ and R-5′- agaggaaaggggcagttgagt – 3′; hInsulin F-5′- gaaccaacacctgtgcggctca - 3′ and R-5′- tgcctgcgggctgcgtctagt - 3′; hGastrin F-5′- cagagccagtgcaaagatca - 3′ and R-5′- agagacctgagaggcaccag - 3′. Note that the gastrin primers do not cross-react with the CCK gene.

Micro-Array analysis

Nkx2.2 and NeuroD

Pancreas tissue was collected from either Nkx2.2^−/−, NeuroD^−/−, Nkx2.2^−/− NeuroD^−/− or WT staged embryos at e14.5 (n = 4). Total pancreata were collected, stored individually in RNase Later (Ambion), and genotyped. Four groups of wild-type and mutant tissues were individually pooled. Samples of total RNA were processed for microarray analysis by using the Mu19k A gene chip according to manufacturer's instructions (Affymetrix). Chip performance, background levels, and presence/absence calls were assessed by using MICROARRAY SUITE software (Affymetrix). The processing of data was performed in GenePattern (Broad Institute).

Ngn3, Arx and Pax4

Pancreas tissue was collected from Ngn3−/−, Arx−/−, Pax4−/− or WT staged embryos at e12.5 (n = 3). Total pancreata were collected and samples of total RNA were processed for microarray analysis using Affymetrix protocol for affymetrix 430 arrays. The processing of data was performed in Genesifter.

Pancreas differentiation from human pluripotent stem cells

Human pluripotent stem cells were differentiated into pancreatic tissue using methods adapted from previous reports [20], [21]. The human embryonic stem cell line WA09 (WiCell) was maintained in feeder-free culture conditions on Matrigel (BD Biosciences) in mTesR1 medium (Stem Cell Technologies). For differentiation, cells were treated with Dispase (Invitrogen) and plated into a 24-well plate. For definitive endoderm induction, 80–90% confluent cells were treated with Activin A (100 ng/ml; R&D Systems) for three days in RPMI 1640 medium (Invitrogen) containing 0%, 0.2%, and 2.0% dFBS (Thermo Scientific) on days 1, 2, and 3. The definitive endoderm was further cultured for two days in the presence of FGF10 (50 ng/ml; R&D Systems) and noggin (50 ng/ml; R&D Systems) in RPMI 1640+2.0% dFBS. For induction of pancreatic endoderm, cells were then treated for four days with all-trans retinoic acid (2 µM; Stemgent), KAAD (0.25 µM; Stemgent), FGF10 (50 ng/ml), and noggin (50 ng/ml) in DMEM medium (Invitrogen) with B27 supplement (2%; Invitrogen). This was followed by five days of culture in EGF (50 ng/ml; R&D Systems) in DMEM/B27, and then six days in Exendin-4 (50 ng/ml; Tocris Bioscience) and DAPT (10 µM; Stemgent) in DMEM/B27.

Statistics

Values are presented as mean ± SE. P values were determined using the 2-tailed Student's t test with unequal variance. P values of less than 0.05 were considered significant. ***, p<0.001, **, p<0.01, * p<0.05.

Supporting Information

Figure S1

Controls for FACS analysis quantifying gastrin⁺ cells in the embryonic pancreas. Left panels: e14.5 pancreata from wild type mice were dissociated to single cells, stained with fluorescent antibodies against either insulin or gastrin and analyzed by FACS. The panels show that in these preps, 0.7% of pancreatic cells are insulin+ and 0.6% are gastrin+ cells. Right panels: e14.5 livers from wild type mice were dissociated to single cells, stained with fluorescent antibodies against insulin and gastrin and analyzed by FACS. The panels show that liver cells are negative both for insulin and gastrin antibodies suggesting for specificity of our antibodies.

(TIF)

Figure S2

More evidence for endocrine cells in the embryonic pancreas that express only gastrin. Sections of e14.5 pancreata co-stained for gastrin (red) and a cocktail of antibodies against insulin, glucagon, somatostatin, pancreatic polypeptide and ghrelin (green). Some cells that stain only for gastrin, while some co-express gastrin and other hormones (appearing in yellow).

(TIF)

Figure S3

Gastrin expressing cells do not stain for CCK. Sections of several e15.5 pancreata stained with an antibody specific for gastrin that does not cross react with CCK (Abnova).

(TIF)

Funding Statement

Funding provided by the Juvenile Diabetes Research Foundation, Beta Cell Biology Consortium (National Institutes of Health (NIH)), The Helmsley Trust, The Dutch Friends of Hebrew University, The European Union Seventh Framework Program (grant n°241883 and ERC), The DON foundation, The I-CORE Program of the Planning and Budgeting Committee, The Israel Science Foundation #41.11 (all to YD), Beta Cell Biology Consortium, NIH, U01 DK072504 (to LS) and YS was supported by a post-doctoral fellowship from JDRF. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.